1. Adjuvant pembrolizumab versus placebo in resected stage III melanoma
- Author
-
Eggermont, Alexander, Blank, Christian, Mandala, Mario, Long, Georgina, Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Lichinitser, Mikhai, Khatta, Adnan, Carlino, Matteo, Sandhu, Shahneen, Larkin, James, Puig, S., Ascierto, P., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A., Grob, J., Gutzmer, R., Jamal, R., Lorigan, Paul C., Ibrahim, N., Marreaud, S., van Akkooi, A., Suciu, S., Robert, C., Eggermont, Alexander, Blank, Christian, Mandala, Mario, Long, Georgina, Atkinson, Victoria, Dalle, Stéphane, Haydon, Andrew, Lichinitser, Mikhai, Khatta, Adnan, Carlino, Matteo, Sandhu, Shahneen, Larkin, James, Puig, S., Ascierto, P., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Maio, M., van den Eertwegh, A., Grob, J., Gutzmer, R., Jamal, R., Lorigan, Paul C., Ibrahim, N., Marreaud, S., van Akkooi, A., Suciu, S., and Robert, C.
- Abstract
Eggermont, A. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., ... & Sandhu, S. (2018). Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. New England Journal of Medicine, 378(19), 1789-1801. Available here